BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded to Outperform at Oppenheimer
Oppenheimer upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a market perform rating to an outperform rating in a research note published on Monday morning, MarketBeat reports. Oppenheimer currently has $98.00 target price on the biotechnology company’s stock. Several other equities analysts have also commented on BMRN. Canaccord Genuity Group decreased their target […]
Oppenheimer upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a market perform rating to an outperform rating in a research note published on Monday morning, MarketBeat reports. Oppenheimer currently has $98.00 target price on the biotechnology company’s stock. Several other equities analysts have also commented on BMRN. Canaccord Genuity Group decreased their target […]
